Cargando…
Increased urokinase and consumption of α(2)‐antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay
ESSENTIALS: Delayed treatment with tranexamic acid results in loss of efficacy and poor outcomes. Increasing urokinase activity may account for adverse effects of late tranexamic acid treatment. Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting. α(2)‐Antiplasmin c...
Autores principales: | Longstaff, C., Locke, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334274/ https://www.ncbi.nlm.nih.gov/pubmed/30451372 http://dx.doi.org/10.1111/jth.14338 |
Ejemplares similares
-
On the localization of the cleavage site in human alpha‐2‐antiplasmin, involved in the generation of the non‐plasminogen binding form
por: Abdul, Shiraazkhan, et al.
Publicado: (2020) -
Fibrinolysis in a lipid environment: modulation through release of free fatty acids
por: RÁBAI, G, et al.
Publicado: (2007) -
Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components
por: Rottenberger, Z, et al.
Publicado: (2013) -
Hindered dissolution of fibrin formed under mechanical stress
por: Varjú, I, et al.
Publicado: (2011) -
Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis
por: Mutch, N J, et al.
Publicado: (2010)